Husam M Salah1, Subhi J Al'Aref1, Muhammad Shahzeb Khan2, Malek Al-Hawwas1, Srikanth Vallurupalli1, Jawahar L Mehta1, J Paul Mounsey1, Stephen J Greene3, Darren K McGuire4, Renato D Lopes5, Marat Fudim6. 1. Division of Cardiology, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR. 2. Department of Medicine, University of Mississippi, Jackson, MS. 3. Division of Cardiology, Department of Medicine, Duke University, Durham, NC; Duke Clinical Research Institute, Durham, NC. 4. Division of Cardiology, Department of Medicine, University Texas Southwestern, and Parkland Health and Hospital System, Dallas, TX. 5. Duke Clinical Research Institute, Durham, NC. 6. Division of Cardiology, Department of Medicine, Duke University, Durham, NC; Duke Clinical Research Institute, Durham, NC. Electronic address: marat.fudim@duke.edu.
Abstract
Sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with improved cardiovascular and kidney outcomes. However, the magnitude and potential heterogeneity of effect across patients with varying types of cardiometabolic and kidney disease is unclear. To examine the effect of SGLT2i on cardiovascular and kidney outcomes among patients with type 2 diabetes mellitus (T2DM), and independent of T2DM status, among patients with heart failure (HF), and chronic kidney disease. METHOD: Medline, Embase, Cochrane library and scientific conferences were searched from inception till September 24, 2020 for randomized controlled trials comparing cardiovascular and kidney outcomes between SGLT2i and placebo. Random effects hazard ratios (HR) with 95% confidence intervals (CIs) were calculated. RESULTS: Eight trials with a combined 59,747 patients were included. In the overall population, SGLT2i reduced the risk of all-cause mortality (HR 0.84; 95% CI [0.78-0.91]), cardiovascular mortality (HR 0.84; 95% CI [0.76-0.93]) hospitalization for HF (HR 0.69; 95% CI [0.64-0.74]), myocardial infarction (HR 0.91; 95% CI [0.84-0.99]), and composite kidney outcome (HR 0.62; 95% CI [0.56-0.70]). There was no significant effect on the risk of stroke (HR 0.98; 95% CI [0.86-1.11]). Results were consistent across subgroups stratified by diabetes and HF status. SGLT2i use was not associated with a greater risk of hypoglycemia (OR 0.92; 95% CI [0.84-1.01]) or amputation (OR 1.25; 95% CI [0.97-1.62]). There were 64 diabetic ketoacidosis events with SGLT2i use and 18 with placebo (OR 2.86; 95% CI [1.39-5.86]). CONCLUSIONS: In patients with cardiometabolic and kidney disease, SGLT2i improved cardiovascular and kidney outcomes, regardless of T2DM, HF, and/or CKD status. The magnitude of risk reduction was largest for hospitalization for HF and progression of kidney disease, more modest for mortality and MI and absent for stroke.
Sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with improved cardiovascular and kidney outcomes. However, the magnitude and potential heterogeneity of effect across patients with varying types of cardiometabolic and kidney disease is unclear. To examine the effect of SGLT2i on cardiovascular and kidney outcomes among patients with type 2 diabetes mellitus (T2DM), and independent of T2DM status, among patients with heart failure (HF), and chronic kidney disease. METHOD: Medline, Embase, Cochrane library and scientific conferences were searched from inception till September 24, 2020 for randomized controlled trials comparing cardiovascular and kidney outcomes between SGLT2i and placebo. Random effects hazard ratios (HR) with 95% confidence intervals (CIs) were calculated. RESULTS: Eight trials with a combined 59,747 patients were included. In the overall population, SGLT2i reduced the risk of all-cause mortality (HR 0.84; 95% CI [0.78-0.91]), cardiovascular mortality (HR 0.84; 95% CI [0.76-0.93]) hospitalization for HF (HR 0.69; 95% CI [0.64-0.74]), myocardial infarction (HR 0.91; 95% CI [0.84-0.99]), and composite kidney outcome (HR 0.62; 95% CI [0.56-0.70]). There was no significant effect on the risk of stroke (HR 0.98; 95% CI [0.86-1.11]). Results were consistent across subgroups stratified by diabetes and HF status. SGLT2i use was not associated with a greater risk of hypoglycemia (OR 0.92; 95% CI [0.84-1.01]) or amputation (OR 1.25; 95% CI [0.97-1.62]). There were 64 diabetic ketoacidosis events with SGLT2i use and 18 with placebo (OR 2.86; 95% CI [1.39-5.86]). CONCLUSIONS: In patients with cardiometabolic and kidney disease, SGLT2i improved cardiovascular and kidney outcomes, regardless of T2DM, HF, and/or CKD status. The magnitude of risk reduction was largest for hospitalization for HF and progression of kidney disease, more modest for mortality and MI and absent for stroke.
Authors: Husam M Salah; Subodh Verma; Carlos G Santos-Gallego; Ankeet S Bhatt; Muthiah Vaduganathan; Muhammad Shahzeb Khan; Renato D Lopes; Subhi J Al'Aref; Darren K McGuire; Marat Fudim Journal: J Cardiovasc Transl Res Date: 2022-03-15 Impact factor: 4.132
Authors: Demetria Hubbard; Lisandro D Colantonio; Robert S Rosenson; Todd M Brown; Elizabeth A Jackson; Lei Huang; Kate K Orroth; Stephanie Reading; Mark Woodward; Vera Bittner; Orlando M Gutierrez; Monika M Safford; Michael E Farkouh; Paul Muntner Journal: Cardiovasc Diabetol Date: 2021-03-01 Impact factor: 9.951
Authors: Javed Butler; Muhammad Shariq Usman; Muhammad Shahzeb Khan; Stephen J Greene; Tim Friede; Muthiah Vaduganathan; Gerasimos Filippatos; Andrew J Stewart Coats; Stefan D Anker Journal: ESC Heart Fail Date: 2020-12
Authors: Swastika Sur; Mark Nguyen; Patrick Boada; Tara K Sigdel; Hans Sollinger; Minnie M Sarwal Journal: Front Immunol Date: 2021-12-01 Impact factor: 7.561